Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 94: 2051-2057, 2003; doi:10.1152/japplphysiol.00845.2002
8750-7587/03 $5.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, Q.
Right arrow Articles by Kotler, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, Q.
Right arrow Articles by Kotler, D. P.
Vol. 94, Issue 5, 2051-2057, May 2003

Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy

Qing He1, Ellen S. Engelson1, Jeanine B. Albu2, Steven B. Heymsfield3, and Donald P. Kotler1

1 Division of Gastroenterology, 2 Division of Endocrinology and Metabolism, Obesity Research Center, and 3 Body Composition Unit, Department of Medicine, St. Luke's-Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, New York, New York 10025

Lipodystrophy with increased intra-abdominal fat in human immunodeficiency virus (HIV) infection is common in the era of highly active antiretroviral therapy. It contributes to the metabolic derangements, as it does in non-HIV-related conditions. Growth hormone administration reduces intra-abdominal fat content. This study compared the relative changes in omental-mesenteric (OMAT) and retroperitoneal adipose tissues (RPAT) during therapy with recombinant human growth hormone (rhGH) in HIV-associated lipodystrophy. Of 30 subjects who began rhGH therapy (6 mg/day), 25 completed 12 wk and 19 completed 24 wk. Fourteen subjects were followed for an additional 12 wk. Volumes of OMAT and RPAT were calculated from total body MRI scans and compared by paired t-tests. Both OMAT and RPAT significantly decreased after 12 and 24 wk of rhGH treatment (P < 0.001), but the reduction was more pronounced in OMAT than in RPAT (P < 0.001). Both OMAT and RPAT increased significantly (P < 0.001) after therapy was discontinued, but OMAT increased significantly more than did RPAT (122 vs. 37%, P < 0.001). There is preferential loss and regain of OMAT, compared with RPAT, in subjects with HIV-associated lipodystrophy undergoing growth hormone treatment.

intra-abdominal adipose tissue; retroperitoneal adipose tissue; visceral adipose tissue; fat redistribution; body composition; human immunodeficiency virus


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
S. D'Amico, J. Shi, R. V Sekhar, F. Jahoor, K. J Ellis, K. Rehman, J. Willis, M. Maldonado, and A. Balasubramanyam
Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome
Am. J. Clinical Nutrition, July 1, 2006; 84(1): 204 - 211.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat
Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting
Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E494 - E503.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online